Citadel Advisors’s Senti Biosciences Holdings SNTI Stock Holding History

Citadel Advisors’s Portfolio SNTI Stock Details SNTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$118K	Buy	+107,100	New	+$105K	﹤0.01%	12556
2025 Q4	–	Sell	-82,753	Closed	-$117K	–	13967
2025 Q3	$117K	Buy	+82,753	New	+$138K	﹤0.01%	11732
2024 Q2	–	Sell	-7,901	Closed	-$29.8K	–	15312
2024 Q1	$29.8K	Buy	7,901 +3,531	+81%	+$15.8K	﹤0.01%	12703
2023 Q4	$28.8K	Buy	+4,370	New	+$17K	﹤0.01%	12302
2022 Q1	–	Sell	-1,507	Closed	-$149K	–	14507
2021 Q4	$149K	Buy	+1,507	New	+$150K	﹤0.01%	12268
2021 Q3	–	Sell	-18,040	Closed	-$1.79M	–	14588
2021 Q2	$1.79M	Buy	+18,040	New	+$1.8M	﹤0.01%	6869

Other funds holding SNTI

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

MVM

Menlo Ventures Management Menlo Park, California $357M AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citadel Advisors's SNTI Position: Q2 2026 in Review

Citadel Advisors opened a new position in Senti Biosciences Holdings (SNTI) in Q2 2026: 107,100 shares worth $118K. The stake represents ﹤0.01% of the portfolio and ranks #12556 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in SNTI as recently as Q3 2025.

Citadel Advisors first reported a position in SNTI in Q2 2021 and has held it in 6 quarters since. The position peaked at $1.79M in Q2 2021. 17 funds tracked by Wall St. Rank hold SNTI as of Q2 2026.

Citadel Advisors held 107,100 shares of Senti Biosciences Holdings worth $118K as of Q2 2026.
Senti Biosciences Holdings was a new Citadel Advisors position in Q2 2026.
Senti Biosciences Holdings made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12556 holding.
Citadel Advisors first reported a position in Senti Biosciences Holdings in Q2 2021 and has held it in 6 quarters since.
Citadel Advisors's Senti Biosciences Holdings position peaked at $1.79M in Q2 2021.
17 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.